Nuclear localization signal-tagged systems: relevant nuclear import principles in the context of current therapeutic design.

Autor: Goswami R; Department of Chemistry, University of Massachusetts, Massachusetts, USA. rotello@chem.umass.edu., Gupta A; Department of Chemistry, University of Massachusetts, Massachusetts, USA. rotello@chem.umass.edu., Bednova O; Département de médecine nucléaire et radiobiologie, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Québec, Canada., Coulombe G; Service des stages et du développement professionnel, Université de Sherbrooke, Sherbrooke, Québec, Canada., Patel D; Service des stages et du développement professionnel, Université de Sherbrooke, Sherbrooke, Québec, Canada., Rotello VM; Department of Chemistry, University of Massachusetts, Massachusetts, USA. rotello@chem.umass.edu., Leyton JV; École des sciences pharmaceutiques, Université d'Ottawa, Ottawa, Ontario, Canada. vleyton@uottawa.ca.; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Publikováno v: Chemical Society reviews [Chem Soc Rev] 2024 Jan 02; Vol. 53 (1), pp. 204-226. Date of Electronic Publication: 2024 Jan 02.

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development.

Autor: Hammood M; Departément de Medécine Nucléaire et Radiobiologie, Faculté de Medécine et des Sciences de la Santé, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada., Craig AW; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada., Leyton JV; Departément de Medécine Nucléaire et Radiobiologie, Faculté de Medécine et des Sciences de la Santé, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.; Centre d'Imagerie Moleculaire, Centre de Recherche, CHUS, Sherbrooke, QC J1H 5N4, Canada.

Publikováno v: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2021 Jul 15; Vol. 14 (7). Date of Electronic Publication: 2021 Jul 15.

A Novel Proteomic Method Reveals NLS Tagging of T-DM1 Contravenes Classical Nuclear Transport in a Model of HER2-Positive Breast Cancer.

Autor: Lacasse V; Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Université de Sherbrooke (UdeS), Sherbrooke, QC J1H 5N4, Canada., Beaudoin S; Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Université de Sherbrooke (UdeS), Sherbrooke, QC J1H 5N4, Canada., Jean S; Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, CHUS, UdeS, Sherbrooke, QC J1H 5N4, Canada., Leyton JV; Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Université de Sherbrooke (UdeS), Sherbrooke, QC J1H 5N4, Canada.; Sherbrooke Molecular Imaging Centre (CIMS), Centre de Recherche du CHUS, UdeS, Sherbrooke, QC J1H 5N4, Canada.

Publikováno v: Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2020 Sep 01; Vol. 19, pp. 99-119. Date of Electronic Publication: 2020 Sep 01 (Print Publication: 2020).

A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts.

Autor: Paquette M; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada., Phoenix S; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada., Lawson C; Department of Anatomy and Cell Biology, Université de Sherbrooke, Québec, Canada., Guérin B; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada.; Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada.; Sherbrooke Pharmacology Institute, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada., Lecomte R; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada.; Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada.; Sherbrooke Pharmacology Institute, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada., Tai LH; Department of Anatomy and Cell Biology, Université de Sherbrooke, Québec, Canada., Turcotte ÉE; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada.; Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada., Leyton JV; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada. Jeffrey.Leyton@Usherbrooke.ca.; Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada. Jeffrey.Leyton@Usherbrooke.ca.; Sherbrooke Pharmacology Institute, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada. Jeffrey.Leyton@Usherbrooke.ca.

Publikováno v: EJNMMI research [EJNMMI Res] 2020 Jun 26; Vol. 10 (1), pp. 69. Date of Electronic Publication: 2020 Jun 26.

CD16 ⁺ NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.

Autor: Williams BA; Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada brentw@uhnres.utoronto.ca brentwilliams.brent@gmail.com.; Institute of Medical Science, University of Toronto, Ontario, Canada., Wang XH; Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Leyton JV; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Quebec, Canada., Maghera S; Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Institute of Medical Science, University of Toronto, Ontario, Canada., Deif B; Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Reilly RM; Department of Medical Imaging, University of Toronto, Ontario, Canada.; Department of Pharmaceutical Sciences, University of Toronto, Ontario, Canada.; Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada., Minden MD; Department of Medical Biophysics, University of Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Ontario, Canada., Keating A; Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Institute of Medical Science, University of Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Ontario, Canada.; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Canada.; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada.

Publikováno v: Haematologica [Haematologica] 2018 Oct; Vol. 103 (10), pp. 1720-1729. Date of Electronic Publication: 2018 Jul 05.